NewcelX AG
nlspharma.comWhat Do They Do?
Develops off-the-shelf stem-cell therapies for patients with diabetes and ALS, and small-molecule drug candidates for sleep and neurodegenerative disorders.
20-F for FY2025, filed Apr 29, 2026NewcelX is a clinical-stage pharmaceutical company focused on developing and manufacturing “off-the-shelf”, allogeneic, proprietary cell…View ↗
NCEL-101 is NewcelX’s lead program for diabetes treatment. NCEL-101 is comprised of enriched pancreatic islet cells, mainly functional…View ↗
AstroRx®, NewcelX’s platform validation product, which is an off-the-shelf cryopreserved cell therapy product in clinical development for…View ↗
In addition, NewcelX is developing DOXA (Dual Orexin-Receptor Agonist) small molecules platform for several target indications, including…View ↗
How Do They Make Money?
No revenue reported yet.
20-F for FY2025, filed Apr 29, 2026
How Are They Changing?
From CNS drug candidates to cell therapies
The older report centered on drug candidates for narcolepsy and other central nervous system disorders. The latest report centers on stem-cell-derived therapies for diabetes and ALS, alongside small-molecule candidates for sleep and neurodegenerative conditions.
20-F for FY2022, filed May 5, 2023 20-F for FY2025, filed Apr 29, 2026NewcelX is a clinical-stage pharmaceutical company focused on developing and manufacturing “off-the-shelf”, allogeneic, proprietary cell…View ↗
NCEL-101 is NewcelX’s lead program for diabetes treatment. NCEL-101 is comprised of enriched pancreatic islet cells, mainly functional…View ↗
AstroRx®, NewcelX’s platform validation product, which is an off-the-shelf cryopreserved cell therapy product in clinical development for…View ↗
In addition, NewcelX is developing DOXA (Dual Orexin-Receptor Agonist) small molecules platform for several target indications, including…View ↗
Who Do They Compete With?
Competes with Vertex Therapeutics, Century Therapeutics, Sana Biotechnology, CellTrans, Corestem, Q Therapeutics, Neuralstem, Brainstorm Cell Therapeutics, Mitsubishi Tanabe Pharmaceuticals, and Amylyx Pharmaceuticals
20-F for FY2025, filed Apr 29, 2026The major market players within the diabetes cell therapy domain and NewcelX’s primary competitors in the United States include Vertex…View ↗
Loading...
